Navigation Links
Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
Date:6/28/2010

age 12 to 45 with new-onset type 1 diabetes. In the confirmatory study, otelixizumab is administered as a single course, given not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes.  The primary endpoint will be a measurement of C-peptide, a surrogate measure of beta cell function that has been endorsed by the U.S. Food and Drug Administration (FDA) at 12 months after dosing.  Maintenance of beta cell function has been associated with improved glycemic control (HbA1c levels), fewer hypoglycemic events, fewer hyperglycemic excursions, and a reduction in long-term disease complications in established type 1 diabetes patients, as referenced in the Diabetes Control and Complications Trial (DCCT).

"Tolerx is aggressively moving forward in our clinical development of otelixizumab.  We are excited by the potential of this novel drug candidate to change the type 1 diabetes treatment paradigm by inhibiting disease progression and perhaps halting the disease by inducing an immunologic remission," said Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx.  "The first patients have been dosed in the DEFEND-2 study, and we believe our study is designed with the robustness and rigor to confirm the efficacy and safety of otelixizumab in a broad patient population."

For additional information about DEFEND-2, please visit www.DefendAgainstDiabetes.com.

About Type 1 Diabetes

Diabetes (medically known as diabetes mellitus) is the name given to disorders in which the body has difficulty regulating its blood glucose (sugar) level. Ther
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
2. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
3. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
4. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
7. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
8. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Cambrex Corporation (NYSE: CBM, "Cambrex") is pleased to announce ... Financial Officer, will present at the Jefferies 2015 Global Healthcare ... New York City . The ... the Cambrex website at www.cambrex.com in the Investors ... available for 90 days after the live event concludes.  ...
(Date:5/27/2015)... , May 27, 2015  Novartis will ... in 21 medicines and 11 investigational compounds across ... American Society of Clinical Oncology (ASCO) Annual Meeting, ... European Hematology Association (EHA), June 11-14. Data will ... cancer types, including melanoma, lung, breast, kidney and ...
(Date:5/27/2015)... , May 25, 2015 Research and Markets ... of the "Research and Future Development Trend Forecast ... offering. At present, there are 35,600 dialysis ... concentration ratio are large due to the different regional ... dialysis centers in other Asian countries are operated by ...
Breaking Medicine Technology:Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 2Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 3Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 4Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 5Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 6Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 7Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA 8China Dialysis Market Report: Research and Future Development Trends and Forecasts 2015-2020 2
(Date:5/27/2015)... The Case Management Society of ... provide CMSA's Career and Knowledge Pathways educational program ... strengthen the case/care management workforce by offering aptitude ... mutually beneficial agreement provides Medix, a workforce solutions ... in the healthcare, scientific and IT industries, access ...
(Date:5/27/2015)... CompanionDx announced that its ... analysis in personalized cancer therapy: Non-small cell lung cancer ... of Clinical Oncology (ASCO) as part of their annual ... The molecular and clinical data used for the study ... The study reports improved patient outcomes from a preliminary ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 This ... current state of the Omega-3 industry. The report ... definitions, classifications, applications and industry chain structure. The ... markets including development trends, competitive landscape analysis, and ... Rieber Oils, Camanchaca Fishing Company, Seadragon Marine Oils, ...
(Date:5/27/2015)... “Heroin has never been more plentiful or cheaper, ... from,” says Harford County Sheriff Jeff Gahler, as quoted by ... surging heroin related incidents in Baltimore, police resources are running ... heroin addiction and subsequent abuse before it turns into a ... is a drug and alcohol rehab facility specializing in heroin ...
(Date:5/27/2015)... May 27, 2015 A television program ... MediaSource and Roswell Park Cancer Institute ... The award-winning story, Cancer Can’t Win , highlights ... Park Cancer Institute. The production team followed five people ... months as they received treatment from doctors and medical ...
Breaking Medicine News(10 mins):Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 2Health News:The Price of Heroin in Baltimore Drops, Surging Use and Causing Rife Overdose Deaths 3Health News:MediaSource Wins New York Emmy® Award as Premier Health Care Storytellers 2Health News:MediaSource Wins New York Emmy® Award as Premier Health Care Storytellers 3
... sharp increase in the number of fat babies; the trend ... the nation’s obesity epidemic//. ,Researchers from the Harvard ... in the July issue of Obesity, have shown a 73.5% ... have said that infants now are 59% more likely to ...
... were many teenagers in Britain who knew as to how ... shown that several of the teens had admitted that they ... off too early. They explained that teenagers with their lack ... the risks of pregnancies and sexually transmitted infections (STI). ...
... Livingston has accused the NHS of giving false information since ... to remove a non-viable fetus. Doctors at the town's St ... womb was dead. ,After this she underwent a procedure ... weeks she found she was still pregnant. "A scan on ...
... of scars following injection with botulinum toxin (BOTOX?) early ... ,The injection prevents muscle movement from wrinkling the wound ... surface for healing and leaving a smoother final scar.,The ... the early healing phase with the injection improves the ...
... School of Medicine have shown the form of a crucial ... to the DNA .The enzyme, which is named, as a ... novel methods to combat small pox. ,"This enzyme ... biology," says Frederic D. Bushman, PhD, Professor of Microbiology, one ...
... a woman from Hamilton was convicted for not informing her doctors ... son// also being infected. ,She was charged for failing ... for child neglect. She was given a 6-month conditional sentence and ... the sentence on 6ht of April but was reported only yesterday ...
Cached Medicine News:Health News:Study finds Babies In America Getting Fatter 2Health News:Teens In UK Do Not Know How To Use A Condom 2Health News:Appearance Of Facial Scars Improved By Botulinum Toxin 2Health News:Appearance Of Facial Scars Improved By Botulinum Toxin 3Health News:Appearance Of Facial Scars Improved By Botulinum Toxin 4Health News:Penn Researchers Throw Light on the Structure Of Smallpox Virus Protein 2
... First Stop absorbable collagen hemostat. FirstStop is ... handling and removal characteristics. It can easily ... fit the wound. FirstStop products are not ... peeled away after hemostasis is achieved. As ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
... D-Stat Flowable Hemostat has a thick, ... application, such as vascular access sites ... is also used as an adjunct ... tissue tracts of femoral access sites ...
The D-Stat Radial hemostat band utilizes a compression band together with the active haemostatic material of the D-Stat to control surface bleeding....
Medicine Products: